UT-MYHERITAGE
25.2.2021 18:24:11 CET | Business Wire | Pressemeddelelse
MyHeritage , den førende globale tjeneste til at opdage din fortid og tage kontrol over din fremtid, annoncerede i dag udgivelsen Deep Nostalgia™ , en ny funktion, der animerer ansigterne i stillbilleder. Deep Nostalgia™ giver slægtshistorien et helt nyt perspektiv ved at producere en realistisk skildring af, hvordan en person kunne have bevæget sig og set ud, hvis de blev fanget på video. MyHeritage er det eneste firma, der tilbyder en komplet pakke af funktioner til farvelægning, gendannelse, forbedring og nu animering af historiske fotos.
Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20210225005924/da/
Teknologien til animering af ansigterne på fotos blev licenseret af MyHeritage fra D-ID , et firma, der specialiserer sig i videogenskabelse ved hjælp af 'deep learning'. Deep Nostalgia™ bruger flere forindspillede driver-videoer udarbejdet af MyHeritage, som styrer bevægelserne i animationen og består af sekvenser af ægte menneskelige bevægelser. En foretrukken driver, baseret på dets retning, vælges automatisk for hvert ansigt, og anvendes derefter problemfrit på fotoet. Resultatet er en kort videoanimation i høj kvalitet af et ansigt, der kan smile, blinke og bevæge sig. For at opnå optimale resultater forbedres billederne inden animationen ved hjælp af MyHeritage Photo Enhancer , som giver slørede ansigter med lav opløsning fokus og øger deres opløsning.
Deep Nostalgia™ er det nyeste AI-baserede fotoværktøj på MyHeritage, og kommer i kølvandet på to meget roste funktioner, som virksomheden udgav sidste år, MyHeritage Photo Enhancer og MyHeritage In Color™ , der farvelægger sorte-hvide fotos og for nylig blev udvidet til også at gendanne farverne i falmede farvefotos. Disse funktioner er blevet virale og brugt over 30 millioner gange. MyHeritage fortsætter med at bygge på dette momentum ved at tilføje nye banebrydende værktøjer til historiske fotos, der inspirerer til en ny forståelse for slægtshistorie og nostalgiske familiefotos.
"Du oplever et 'wow-øjeblik', når du ser et værdsat familiefoto komme til live med Deep Nostalgia™”, sagde Gilad Japhet, grundlægger og administrerende direktør for MyHeritage. "At se vores elskede forfædres ansigter komme til live i en videosimulering giver os mulighed for at forestille os, hvordan de kunne have været i virkeligheden, og giver en helt ny måde at blive forbundet til vores slægtshistorie."
"Denne nye produktintegration er et spændende samarbejde mellem to innovative virksomheder," sagde Gil Perry, medstifter og administrerende direktør for D-ID. "Vi er begejstrede for, at vores teknologi vil være tilgængelig for millioner af mennesker på MyHeritage, og vi håber, at mange af dem vil nyde virkningen af videogenskabelse af historiske fotos."
Integration i MyHeritage-platformen
Deep Nostalgia™ er en freemium-funktion på MyHeritage. Brugere kan animere flere fotos gratis, uanset antallet af ansigter på billedet. Ud over det kræver fortsat brug et abonnement. Videoanimationen kan let deles med familie og venner på Facebook, Twitter, WhatsApp og andre sociale medier.
Om MyHeritage
MyHeritage er den førende globale platform til at opdage og udforske slægtshistorie. Med milliarder af historiske optegnelser og slægttræsprofiler og med sofistikerede matching-teknologier på tværs af alle dens aktiver, giver MyHeritage brugere mulighed for at opdage deres fortid og tage kontrol over deres fremtid. MyHeritage DNA er en af verdens største DNA-databaser med 4,7 millioner kunder. MyHeritage er den mest populære tjeneste for DNA-test og slægtsforskning i Europa. Siden 2020 er MyHeritage hjemsted for verdens bedste AI-teknologier til forbedring og farvelægning af historiske fotos. www.myheritage.dk
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20210225005924/da/
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum